MATINAS BIOPHARMA HOLDINGS, INC. Proceeds from Sale of Buildings
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Proceeds from Sale of Buildings of $335.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfBuildings · last filed 2026-03-31
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from sale of buildings for the quarter ending 2025-12-31 was $15.00K.
- MATINAS BIOPHARMA HOLDINGS, INC. proceeds from sale of buildings for fiscal 2025 was $335.00K.
| Period end | Proceeds from Sale of Buildings 3 month | Proceeds from Sale of Buildings 9 month | Proceeds from Sale of Buildings 12 month |
|---|---|---|---|
| 2025-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $335.00K 10-K · filed 2026-03-31 | |
| 2025-09-30 | $320.00K 10-Q · filed 2025-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |